Rapid Early Action for Coronary Treatment (REACT)
Launched by CARELON RESEARCH · Oct 27, 1999
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Since the advent of thrombolytic therapy, early treatment holds particular promise for decreasing mortality from coronary heart disease. Thrombolytic therapy can reduce mortality by 25 percent for patients treated within the first few hours of AMI symptoms, with greater benefit the earlier the treatment. Not everyone who could benefit from receiving thrombolytic therapy receives such therapy. One contributing factor is that many people with symptoms do not seek emergency care in a timely manner. Studies show substantial delay times from AMI symptoms to hospital arrival, with me...
Gender
ALL
Eligibility criteria
- • Men and women with acute MI or unstable angina.
About Carelon Research
Carelon Research is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on delivering high-quality clinical trials across various therapeutic areas, Carelon Research collaborates with healthcare professionals, institutions, and patients to ensure the integrity and efficacy of its studies. The organization is committed to ethical practices and compliance, fostering an environment of transparency and collaboration. By leveraging cutting-edge technology and a patient-centric approach, Carelon Research aims to accelerate the discovery of new therapies that enhance patient outcomes and contribute to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Henry Feldman
New England Research Institute, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials